Skip to Content

Docetaxel Teva Pharma

Active Substance: docetaxel
Common Name: docetaxel
ATC Code: L01CD02
Marketing Authorisation Holder: Teva Pharma B.V.
Active Substance: docetaxel
Status: Withdrawn
Authorisation Date: 2011-01-21
Therapeutic Area: Carcinoma, Non-Small-Cell Lung Prostatic Neoplasms Breast Neoplasms
Pharmacotherapeutic Group: Antineoplastic agents

Therapeutic Indication

Breast cancer

Docetaxel Teva Pharma monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.

Non-small-cell lung cancer

Docetaxel Teva Pharma is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.

Docetaxel Teva Pharma in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.

Prostate cancer

Docetaxel Teva Pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

The marketing authorisation for Docetaxel Teva Pharma has lapsed because it ceased to be marketed in the European Union more than three years ago and an exemption granted by the European Commission has expired.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide